OPTHEA LTD (SP.ADR/8) (F:UKJ2) — Market Cap & Net Worth
Market Cap & Net Worth: OPTHEA LTD (SP.ADR/8) (UKJ2)
OPTHEA LTD (SP.ADR/8) (F:UKJ2) has a market capitalization of $512.99 Million (€438.79 Million) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #12409 globally and #1328 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OPTHEA LTD (SP.ADR/8)'s stock price €3.00 by its total outstanding shares 170997272 (171.00 Million).
OPTHEA LTD (SP.ADR/8) Market Cap History: 2020 to 2026
OPTHEA LTD (SP.ADR/8)'s market capitalization history from 2020 to 2026. Data shows change from $1.81 Billion to $599.74 Million (-21.21% CAGR).
OPTHEA LTD (SP.ADR/8) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OPTHEA LTD (SP.ADR/8)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of UKJ2 by Market Capitalization
Companies near OPTHEA LTD (SP.ADR/8) in the global market cap rankings as of May 2, 2026.
Key companies related to OPTHEA LTD (SP.ADR/8) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
OPTHEA LTD (SP.ADR/8) Historical Marketcap From 2020 to 2026
Between 2020 and today, OPTHEA LTD (SP.ADR/8)'s market cap moved from $1.81 Billion to $ 599.74 Million, with a yearly change of -21.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €599.74 Million | 0.00% |
| 2025 | €599.74 Million | -18.48% |
| 2024 | €735.68 Million | +40.46% |
| 2023 | €523.77 Million | -43.29% |
| 2022 | €923.60 Million | -29.47% |
| 2021 | €1.31 Billion | -27.62% |
| 2020 | €1.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of OPTHEA LTD (SP.ADR/8) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $512.99 Million USD |
| MoneyControl | $512.99 Million USD |
| MarketWatch | $512.99 Million USD |
| marketcap.company | $512.99 Million USD |
| Reuters | $512.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OPTHEA LTD (SP.ADR/8)
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more